Anti-Obesity Prescription Drugs Market size is expected to grow at 4.9% throughout the forecast period, reaching nearly US$ 3.78 Bn by 2029. According to past study 650 Mn individuals in 1965 had corpulent body and recent study data shows the obesity has tripled in 2022, giving a number of 1.6 Bn individuals who are suffering from overweight problems. A corpulent individual is at a higher risk of developing chronic diseases like endometrial cancer, breast cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.To know about the Research Methodology :- Request Free Sample Report The drug which inhibit fat absorption, energy intake, enhance energy expenditure and stimulate fat mobilization are known as Anti-Obesity Drugs. The FDA has approved five different types of Anti-Obesity Prescription Drugs lorcaserin (Belviq), orlistat (Xenical), phentermine-topiramate (Qsymia), naltrexone-bupropion (Contrave), and liraglutide (Saxenda).Global Anti-Obesity Prescription Drugs Market Drivers and RestrainsThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. According to, Disease Control & Prevention Centers show that 68.8% of the United State population is obese. The increasing incidence of the condition is followed by growing awareness of the same. Because of, the increasing awareness of anxiety that customers shift to anti-obesity drugs is rising at a prominent step. Obesity can be credited as an incurable chronic disease that increases the risk of cardiovascular diseases like diabetes, hypertension, and strokes. Sometimes, lifestyle intervention fails to impart potential results and a huge proportion of patients obvert their customary standards to enhance positive clinical outcome with the consumption of prescribed weight loss drugs. Advanced technique of skin patch delivery that permits for the administration of anti-obesity prescription drugs with low risk of side effects. Furthermore, the development of Nano Soy-Phytosome based thermo gels as the interesting formulations of anti-obesity is a key novelty in the market. Herbal supplements are the recent trend in the anti-obesity prescription drugs market. These trends are expected to boost opportunities for the growth of sellers in the global anti-obesity drugs market. The top Food and Drug Administration (FDA) approved anti-obesity drugs are Contrave, Belviq, Xenical, Saxenda and Qsymia. In United State, Xenical was the largest selling drug in the market until 2012, because of the character for unpleasant gastrointestinal side effects showed by Xenical. Though, recently approved Saxenda by Novo Nordisk Pharma is gaining large interest between obese individuals and is growing at a unanimous rate. Manufacturers in the Anti-Obesity Prescription Drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.
Segment Analysis
The anti-obesity Prescription drugs market is segmented on the basis of Type, drug class, sales channel, Application, and region. In terms of drug class, it is segmented into peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs. In terms of type, it is segmented into prescription drugs and OTC drugs are of two main types. These cover a host of pharmacological agents that reduce or control weight by altering either the absorption of calories or regulating hunger. In terms of sales channel, market is devided into Direct Channel and Distribution Channel. The key players have identified distribution channels to classify the market into Hospital Pharmacies, E-Commerce, and Retail Pharmacies among others. Pharmaceutical companies, like AstraZeneca, J&J, and Sanofi, are assuming low-risk strategy of using diabetes drugs to treat the obesity related problem. Johnson & Johnson is projected to enter the market for prescription anti-obesity drugs without further capitalizing in the development of novel molecules. By Applications market is segmented into Hospitals Pharmacies, Retail Pharmacie, E-commerce and others. Hospitals and Retail Pharmacies segment is expected to exhibit highest global market share at a CAGR of xx % over forecast period.Regional Insights
In terms of regional analysis North America is expected to emerge as a leading region in the global anti-obesity prescription drugs market during the forecast period. Because of the awareness of obesity among the population and the risks associated with the health situation have resulted in the anti-obesity prescription drugs market describing flourished growth in the region over the years. The Asia Pacific market for anti-obesity prescription drugs is anticipated to drive in the coming years, thanks to the rise in obese population. The European Medicines Agency (EMA), retreated the utilization of a series of anti-obesity drugs attributed to prohibited proportion of threat to benefit ratio, in 2000. Anti-obesity prescriptive drug like Rimonabant was available in more than 55 countries Afterward, in the year 2009 Rimonabant was withdrawn from the European anti-obesity prescription drugs market due to serious psychiatric side effects. In recent times, numerous development have been tested and examined, but only orlistat and sibutramine have been permitted for long-term use. The objective of the report is to present comprehensive analysis of Global Anti-Obesity Prescription Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Anti-Obesity Prescription Drugs Market dynamics, structure by analyzing the market segments, and project the Global Anti-Obesity Prescription Drugs Market size. Clear representation of competitive analysis of key players by Anti-Obesity Prescription Drugs Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-Obesity Prescription Drugs Market make the report investor’s guide.Anti-Obesity Prescription Drugs Market Scope: Inquire before buying
Anti-Obesity Prescription Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 2.70 Bn. Forecast Period 2023 to 2029 CAGR: 4.9% Market Size in 2029: US $ 3.78 Bn. Segments Covered: by Drug Type Contrave Belviq Xenical Saxenda Qsymia by Type Prescription Drugs OTC Drugs by Drug class Peripherally Acting Anti-obesity Drugs Centrally Acting Anti-obesity Drugs by Sales channel Direct Channel Distribution Channel by Application Hospitals Pharmacies Retail Pharmacies E-commerce Anti-Obesity Prescription Drugs Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Anti-Obesity Prescription Drugs Market, Key Players
1. F Hoffmann La Roche 2. Arena Pharmaceuticals 3. Orexigen Therapeutics 4. Phentermine and Topiramate 5. VIVUS, Inc 6. Liraglutide 7. Bupropion and Naltrexone 8. Orlistat 9. Novo Nordisk 10.Lorcaserin 11.GlaxoSmith Kline 12.Eisai Co, Ltd 13.Boehringer Ingelheim 14.Merck & Co 15.Pfizer 16.Rhythm Pharmaceuticals 17.Zafgan 18.Takeda Pharmaceuticals 19.Novo Nordisk 20.Bristol-Myers Squibb Co. 21.Shionogi USA Inc 22.Norgine by Frequently Asked Questions: 1. Which region has the largest share in Global Anti-Obesity Prescription Drugs Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Anti-Obesity Prescription Drugs Market? Ans: The global market is growing at a CAGR of 4.9% during forecasting period 2023-2029. 3. What is scope of the Global Anti-Obesity Prescription Drugs market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Anti-Obesity Prescription Drugs market? Ans: The important key players in the global market are – Phentermine and Topiramate, VIVUS, Inc, F Hoffmann La Roche, Liraglutide, Norgine bv, Bupropion and Naltrexone, Orlistat, Novo Nordisk, Lorcaserin, GlaxoSmith Kline, Eisai Co, Ltd, Boehringer Ingelheim, Merck & Co, Pfizer, Rhythm Pharmaceuticals, Zafgan, Takeda Pharmaceuticals, Novo Nordisk, Bristol-Myers Squibb Co., and Shionogi USA Inc. 5. What is the study period of this market? Ans: The Global Anti-Obesity Prescription Drugs Market is studied from 2022 to 2029.
Global Anti-Obesity Prescription Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Anti-Obesity Prescription Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast 6.1. Global Anti-Obesity Prescription Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast, By Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Anti-Obesity Prescription Drugs Market Value Share Analysis, By Type 7.4. Global Anti-Obesity Prescription Drugs Market Size (US$ Bn) Forecast, By Type 7.5. Global Anti-Obesity Prescription Drugs Market Analysis, By Type 7.6. Global Anti-Obesity Prescription Drugs Market Attractiveness Analysis, By Type 8. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast, By Drug Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug Type 8.4. Global Anti-Obesity Prescription Drugs Market Size (US$ Bn) Forecast, By Drug Type 8.5. Global Anti-Obesity Prescription Drugs Market Analysis, By Drug Type 8.6. Global Anti-Obesity Prescription Drugs Market Attractiveness Analysis, By Drug Type 9. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast, By Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Anti-Obesity Prescription Drugs Market Value Share Analysis, By Application 9.4. Global Anti-Obesity Prescription Drugs Market Size (US$ Bn) Forecast, By Application 9.5. Global Anti-Obesity Prescription Drugs Market Analysis, By Application 9.6. Global Anti-Obesity Prescription Drugs Market Attractiveness Analysis, By Application 10. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast, By Drug class 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug class 10.4. Global Anti-Obesity Prescription Drugs Market Size (US$ Bn) Forecast, By Drug class 10.5. Global Anti-Obesity Prescription Drugs Market Analysis, By Drug class 10.6. Global Anti-Obesity Prescription Drugs Market Attractiveness Analysis, By Drug class 11. Global Anti-Obesity Prescription Drugs Market Analysis and Forecast, By Sales channel 11.1. Introduction and Definition 11.2. Key Findings 11.3. Global Anti-Obesity Prescription Drugs Market Value Share Analysis, By Sales channel 11.4. Global Anti-Obesity Prescription Drugs Market Size (US$ Bn) Forecast, By Sales channel 11.5. Global Anti-Obesity Prescription Drugs Market Analysis, By Sales channel 11.6. Global Anti-Obesity Prescription Drugs Market Attractiveness Analysis, By Sales channel 12. Global Anti-Obesity Prescription Drugs Market Analysis, by Region 12.1. Global Anti-Obesity Prescription Drugs Market Value Share Analysis, by Region 12.2. Global Anti-Obesity Prescription Drugs Market Size (US$ Bn) Forecast, by Region 12.3. Global Anti-Obesity Prescription Drugs Market Attractiveness Analysis, by Region 13. North America Anti-Obesity Prescription Drugs Market Analysis 13.1. Key Findings 13.2. North America Anti-Obesity Prescription Drugs Market Overview 13.3. North America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Type 13.4. North America Anti-Obesity Prescription Drugs Market Forecast, By Type 13.4.1. PRESCRIPTION DRUGS 13.4.2. OTC Drugs 13.5. North America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug Type 13.6. North America Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 13.6.1. Contrave 13.6.2. Belviq 13.6.3. Xenical 13.6.4. Saxenda 13.6.5. Qsymia 13.7. North America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Application 13.8. North America Anti-Obesity Prescription Drugs Market Forecast, By Application 13.8.1. HOSPITALS PHARMACIES 13.8.2. RETAIL PHARMACIES 13.8.3. E-COMMERCE 13.9. North America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug class 13.10. North America Anti-Obesity Prescription Drugs Market Forecast, By Drug class 13.10.1. Peripherally Acting Anti-obesity Drugs 13.10.2. Centrally Acting Anti-obesity Drugs 13.11. North America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Sales channel 13.12. North America Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 13.12.1. Direct Channel 13.12.2. Distribution Channel 13.13. North America Anti-Obesity Prescription Drugs Market Value Share Analysis, by Country 13.14. North America Anti-Obesity Prescription Drugs Market Forecast, by Country 13.14.1. U.S. 13.14.2. Canada 13.15. North America Anti-Obesity Prescription Drugs Market Analysis, by Country 13.16. U.S. Anti-Obesity Prescription Drugs Market Forecast, By Type 13.16.1. PRESCRIPTION DRUGS 13.16.2. OTC Drugs 13.17. U.S. Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 13.17.1. Contrave 13.17.2. Belviq 13.17.3. Xenical 13.17.4. Saxenda 13.17.5. Qsymia 13.18. U.S. Anti-Obesity Prescription Drugs Market Forecast, By Application 13.18.1. HOSPITALS PHARMACIES 13.18.2. RETAIL PHARMACIES 13.18.3. E-COMMERCE 13.19. U.S. Anti-Obesity Prescription Drugs Market Forecast, By Drug class 13.19.1. Peripherally Acting Anti-obesity Drugs 13.19.2. Centrally Acting Anti-obesity Drugs 13.20. U.S. Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 13.20.1. Direct Channel 13.20.2. Distribution Channel 13.21. Canada Anti-Obesity Prescription Drugs Market Forecast, By Type 13.21.1. PRESCRIPTION DRUGS 13.21.2. OTC Drugs 13.22. Canada Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 13.22.1. Contrave 13.22.2. Belviq 13.22.3. Xenical 13.22.4. Saxenda 13.22.5. Qsymia 13.23. Canada Anti-Obesity Prescription Drugs Market Forecast, By Application 13.23.1. HOSPITALS PHARMACIES 13.23.2. RETAIL PHARMACIES 13.23.3. E-COMMERCE 13.24. Canada Anti-Obesity Prescription Drugs Market Forecast, By Drug class 13.24.1. Peripherally Acting Anti-obesity Drugs 13.24.2. Centrally Acting Anti-obesity Drugs 13.25. Canada Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 13.25.1. Direct Channel 13.25.2. Distribution Channel 13.26. North America Anti-Obesity Prescription Drugs Market Attractiveness Analysis 13.26.1. By Type 13.26.2. By Drug Type 13.26.3. By Application 13.26.4. By Drug class 13.26.5. By Sales channel 13.27. PEST Analysis 13.28. Key Trends 13.29. Key Developments 14. Europe Anti-Obesity Prescription Drugs Market Analysis 14.1. Key Findings 14.2. Europe Anti-Obesity Prescription Drugs Market Overview 14.3. Europe Anti-Obesity Prescription Drugs Market Value Share Analysis, By Type 14.4. Europe Anti-Obesity Prescription Drugs Market Forecast, By Type 14.4.1. PRESCRIPTION DRUGS 14.4.2. OTC Drugs 14.5. Europe Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug Type 14.6. Europe Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 14.6.1. Contrave 14.6.2. Belviq 14.6.3. Xenical 14.6.4. Saxenda 14.6.5. Qsymia 14.7. Europe Anti-Obesity Prescription Drugs Market Value Share Analysis, By Application 14.8. Europe Anti-Obesity Prescription Drugs Market Forecast, By Application 14.8.1. HOSPITALS PHARMACIES 14.8.2. RETAIL PHARMACIES 14.8.3. E-COMMERCE 14.9. Europe Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug class 14.10. Europe Anti-Obesity Prescription Drugs Market Forecast, By Drug class 14.10.1. Peripherally Acting Anti-obesity Drugs 14.10.2. Centrally Acting Anti-obesity Drugs 14.11. Europe Anti-Obesity Prescription Drugs Market Value Share Analysis, By Sales channel 14.12. Europe Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 14.12.1. Direct Channel 14.12.2. Distribution Channel 14.13. Europe Anti-Obesity Prescription Drugs Market Value Share Analysis, by Country 14.14. Europe Anti-Obesity Prescription Drugs Market Forecast, by Country 14.14.1. Germany 14.14.2. U.K. 14.14.3. France 14.14.4. Italy 14.14.5. Spain 14.14.6. Rest of Europe 14.15. Europe Anti-Obesity Prescription Drugs Market Analysis, by Country 14.16. Germany Anti-Obesity Prescription Drugs Market Forecast, By Type 14.16.1. PRESCRIPTION DRUGS 14.16.2. OTC Drugs 14.17. Germany Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 14.17.1. Contrave 14.17.2. Belviq 14.17.3. Xenical 14.17.4. Saxenda 14.17.5. Qsymia 14.18. Germany Anti-Obesity Prescription Drugs Market Forecast, By Application 14.18.1. HOSPITALS PHARMACIES 14.18.2. RETAIL PHARMACIES 14.18.3. E-COMMERCE 14.19. Germany Anti-Obesity Prescription Drugs Market Forecast, By Drug class 14.19.1. Peripherally Acting Anti-obesity Drugs 14.19.2. Centrally Acting Anti-obesity Drugs 14.20. Germany Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 14.20.1. Direct Channel 14.20.2. Distribution Channel 14.21. U.K. Anti-Obesity Prescription Drugs Market Forecast, By Type 14.21.1. PRESCRIPTION DRUGS 14.21.2. OTC Drugs 14.22. U.K. Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 14.22.1. Contrave 14.22.2. Belviq 14.22.3. Xenical 14.22.4. Saxenda 14.22.5. Qsymia 14.23. U.K. Anti-Obesity Prescription Drugs Market Forecast, By Application 14.23.1. HOSPITALS PHARMACIES 14.23.2. RETAIL PHARMACIES 14.23.3. E-COMMERCE 14.24. U.K. Anti-Obesity Prescription Drugs Market Forecast, By Drug class 14.24.1. Peripherally Acting Anti-obesity Drugs 14.24.2. Centrally Acting Anti-obesity Drugs 14.25. U.K. Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 14.25.1. Direct Channel 14.25.2. Distribution Channel 14.26. France Anti-Obesity Prescription Drugs Market Forecast, By Type 14.26.1. PRESCRIPTION DRUGS 14.26.2. OTC Drugs 14.27. France Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 14.27.1. Contrave 14.27.2. Belviq 14.27.3. Xenical 14.27.4. Saxenda 14.27.5. Qsymia 14.28. France Anti-Obesity Prescription Drugs Market Forecast, By Application 14.28.1. Hospitals Pharmacies 14.28.2. RETAIL PHARMACIES 14.28.3. E-COMMERCE 14.29. France Anti-Obesity Prescription Drugs Market Forecast, By Drug class 14.29.1. Peripherally Acting Anti-obesity Drugs 14.29.2. Centrally Acting Anti-obesity Drugs 14.30. France Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 14.30.1. Direct Channel 14.30.2. Distribution Channel 14.31. Italy Anti-Obesity Prescription Drugs Market Forecast, By Type 14.31.1. PRESCRIPTION DRUGS 14.31.2. OTC Drugs 14.32. Italy Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 14.32.1. Contrave 14.32.2. Belviq 14.32.3. Xenical 14.32.4. Saxenda 14.32.5. Qsymia 14.33. Italy Anti-Obesity Prescription Drugs Market Forecast, By Application 14.33.1. HOSPITALS PHARMACIES 14.33.2. RETAIL PHARMACIES 14.33.3. E-COMMERCE 14.34. Italy Anti-Obesity Prescription Drugs Market Forecast, By Drug class 14.34.1. Peripherally Acting Anti-obesity Drugs 14.34.2. Centrally Acting Anti-obesity Drugs 14.35. Italy Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 14.35.1. Direct Channel 14.35.2. Distribution Channel 14.36. Spain Anti-Obesity Prescription Drugs Market Forecast, By Type 14.36.1. PRESCRIPTION DRUGS 14.36.2. OTC Drugs 14.37. Spain Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 14.37.1. Contrave 14.37.2. Belviq 14.37.3. Xenical 14.37.4. Saxenda 14.37.5. Qsymia 14.38. Spain Anti-Obesity Prescription Drugs Market Forecast, By Application 14.38.1. HOSPITALS PHARMACIES 14.38.2. RETAIL PHARMACIES 14.38.3. E-COMMERCE 14.39. Spain Anti-Obesity Prescription Drugs Market Forecast, By Drug class 14.39.1. Peripherally Acting Anti-obesity Drugs 14.39.2. Centrally Acting Anti-obesity Drugs 14.40. Spain Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 14.40.1. Direct Channel 14.40.2. Distribution Channel 14.41. Rest of Europe Anti-Obesity Prescription Drugs Market Forecast, By Type 14.41.1. PRESCRIPTION DRUGS 14.41.2. OTC Drugs 14.42. Rest of Europe Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 14.42.1. Contrave 14.42.2. Belviq 14.42.3. Xenical 14.42.4. Saxenda 14.42.5. Qsymia 14.43. Rest of Europe Anti-Obesity Prescription Drugs Market Forecast, By Application 14.43.1. HOSPITALS PHARMACIES 14.43.2. RETAIL PHARMACIES 14.43.3. E-COMMERCE 14.44. Rest Of Europe Anti-Obesity Prescription Drugs Market Forecast, By Drug class 14.44.1. Peripherally Acting Anti-obesity Drugs 14.44.2. Centrally Acting Anti-obesity Drugs 14.45. Rest Of Europe Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 14.45.1. Direct Channel 14.45.2. Distribution Channel 14.46. Europe Anti-Obesity Prescription Drugs Market Attractiveness Analysis 14.46.1. By Type 14.46.2. By Drug Type 14.46.3. By Application 14.46.4. By Drug class 14.46.5. By Sales channel 14.47. PEST Analysis 14.48. Key Trends 14.49. Key Developments 15. Asia Pacific Anti-Obesity Prescription Drugs Market Analysis 15.1. Key Findings 15.2. Asia Pacific Anti-Obesity Prescription Drugs Market Overview 15.3. Asia Pacific Anti-Obesity Prescription Drugs Market Value Share Analysis, By Type 15.4. Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Type 15.4.1. PRESCRIPTION DRUGS 15.4.2. OTC Drugs 15.5. Asia Pacific Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug Type 15.6. Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 15.6.1. Contrave 15.6.2. Belviq 15.6.3. Xenical 15.6.4. Saxenda 15.6.5. Qsymia 15.7. Asia Pacific Anti-Obesity Prescription Drugs Market Value Share Analysis, By Application 15.8. Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Application 15.8.1. HOSPITALS PHARMACIES 15.8.2. RETAIL PHARMACIES 15.8.3. E-COMMERCE 15.9. Asia Pacific Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug class 15.10. Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Drug class 15.10.1. Peripherally Acting Anti-obesity Drugs 15.10.2. Centrally Acting Anti-obesity Drugs 15.11. Asia Pacific Anti-Obesity Prescription Drugs Market Value Share Analysis, By Sales channel 15.12. Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 15.12.1. Direct Channel 15.12.2. Distribution Channel 15.13. Asia Pacific Anti-Obesity Prescription Drugs Market Value Share Analysis, by Country 15.14. Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, by Country 15.14.1. China 15.14.2. India 15.14.3. Japan 15.14.4. ASEAN 15.14.5. Rest of Asia Pacific 15.15. Asia Pacific Anti-Obesity Prescription Drugs Market Analysis, by Country 15.16. China Anti-Obesity Prescription Drugs Market Forecast, By Type 15.16.1. PRESCRIPTION DRUGS 15.16.2. OTC Drugs 15.17. China Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 15.17.1. Contrave 15.17.2. Belviq 15.17.3. Xenical 15.17.4. Saxenda 15.17.5. Qsymia 15.18. China Anti-Obesity Prescription Drugs Market Forecast, By Application 15.18.1. HOSPITALS PHARMACIES 15.18.2. RETAIL PHARMACIES 15.18.3. E-COMMERCE 15.19. China Anti-Obesity Prescription Drugs Market Forecast, By Drug class 15.19.1. Peripherally Acting Anti-obesity Drugs 15.19.2. Centrally Acting Anti-obesity Drugs 15.20. China Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 15.20.1. Direct Channel 15.20.2. Distribution Channel 15.21. India Anti-Obesity Prescription Drugs Market Forecast, By Type 15.21.1. PRESCRIPTION DRUGS 15.21.2. OTC Drugs 15.22. India Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 15.22.1. Contrave 15.22.2. Belviq 15.22.3. Xenical 15.22.4. Saxenda 15.22.5. Qsymia 15.23. India Anti-Obesity Prescription Drugs Market Forecast, By Application 15.23.1. HOSPITALS PHARMACIES 15.23.2. RETAIL PHARMACIES 15.23.3. E-COMMERCE 15.24. India Anti-Obesity Prescription Drugs Market Forecast, By Drug class 15.24.1. Peripherally Acting Anti-obesity Drugs 15.24.2. Centrally Acting Anti-obesity Drugs 15.25. India Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 15.25.1. Direct Channel 15.25.2. Distribution Channel 15.26. Japan Anti-Obesity Prescription Drugs Market Forecast, By Type 15.26.1. PRESCRIPTION DRUGS 15.26.2. OTC Drugs 15.27. Japan Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 15.27.1. Contrave 15.27.2. Belviq 15.27.3. Xenical 15.27.4. Saxenda 15.27.5. Qsymia 15.28. Japan Anti-Obesity Prescription Drugs Market Forecast, By Application 15.28.1. HOSPITALS PHARMACIES 15.28.2. RETAIL PHARMACIES 15.28.3. E-COMMERCE 15.29. Japan Anti-Obesity Prescription Drugs Market Forecast, By Drug class 15.29.1. Peripherally Acting Anti-obesity Drugs 15.29.2. Centrally Acting Anti-obesity Drugs 15.30. Japan Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 15.30.1. Direct Channel 15.30.2. Distribution Channel 15.31. ASEAN Anti-Obesity Prescription Drugs Market Forecast, By Type 15.31.1. PRESCRIPTION DRUGS 15.31.2. OTC Drugs 15.32. ASEAN Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 15.32.1. Contrave 15.32.2. Belviq 15.32.3. Xenical 15.32.4. Saxenda 15.32.5. Qsymia 15.33. ASEAN Anti-Obesity Prescription Drugs Market Forecast, By Application 15.33.1. HOSPITALS PHARMACIES 15.33.2. RETAIL PHARMACIES 15.33.3. E-COMMERCE 15.34. ASEAN Anti-Obesity Prescription Drugs Market Forecast, By Drug class 15.34.1. Peripherally Acting Anti-obesity Drugs 15.34.2. Centrally Acting Anti-obesity Drugs 15.35. ASEAN Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 15.35.1. Direct Channel 15.35.2. Distribution Channel 15.36. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Type 15.36.1. PRESCRIPTION DRUGS 15.36.2. OTC Drugs 15.37. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 15.37.1. Contrave 15.37.2. Belviq 15.37.3. Xenical 15.37.4. Saxenda 15.37.5. Qsymia 15.38. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Application 15.38.1. HOSPITALS PHARMACIES 15.38.2. RETAIL PHARMACIES 15.38.3. E-COMMERCE 15.39. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Drug class 15.39.1. Peripherally Acting Anti-obesity Drugs 15.39.2. Centrally Acting Anti-obesity Drugs 15.40. Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 15.40.1. Direct Channel 15.40.2. Distribution Channel 15.41. Asia Pacific Anti-Obesity Prescription Drugs Market Attractiveness Analysis 15.41.1. By Type 15.41.2. By Drug Type 15.41.3. By Application 15.41.4. By Drug class 15.41.5. By Sales channel 15.42. PEST Analysis 15.43. Key Trends 15.44. Key Developments 16. Middle East & Africa Anti-Obesity Prescription Drugs Market Analysis 16.1. Key Findings 16.2. Middle East & Africa Anti-Obesity Prescription Drugs Market Overview 16.3. Middle East & Africa Anti-Obesity Prescription Drugs Market Value Share Analysis, By Type 16.4. Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Type 16.4.1. PRESCRIPTION DRUGS 16.4.2. OTC Drugs 16.5. Middle East & Africa Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug Type 16.6. Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 16.6.1. Contrave 16.6.2. Belviq 16.6.3. Xenical 16.6.4. Saxenda 16.6.5. Qsymia 16.7. Middle East & Africa Anti-Obesity Prescription Drugs Market Value Share Analysis, By Application 16.8. Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Application 16.8.1. HOSPITALS PHARMACIES 16.8.2. RETAIL PHARMACIES 16.8.3. E-COMMERCE 16.9. Middle East & Africa Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug class 16.10. Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Drug class 16.10.1. Peripherally Acting Anti-obesity Drugs 16.10.2. Centrally Acting Anti-obesity Drugs 16.11. Middle East & Africa Anti-Obesity Prescription Drugs Market Value Share Analysis, By Sales channel 16.12. Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 16.12.1. Direct Channel 16.12.2. Distribution Channel 16.13. Middle East & Africa Anti-Obesity Prescription Drugs Market Value Share Analysis, by Country 16.14. Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, by Country 16.14.1. GCC 16.14.2. South Africa 16.14.3. Rest of Middle East & Africa 16.15. Middle East & Africa Anti-Obesity Prescription Drugs Market Analysis, by Country 16.16. GCC Anti-Obesity Prescription Drugs Market Forecast, By Type 16.16.1. PRESCRIPTION DRUGS 16.16.2. OTC Drugs 16.17. GCC Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 16.17.1. Contrave 16.17.2. Belviq 16.17.3. Xenical 16.17.4. Saxenda 16.17.5. Qsymia 16.18. GCC Anti-Obesity Prescription Drugs Market Forecast, By Application 16.18.1. HOSPITALS PHARMACIES 16.18.2. RETAIL PHARMACIES 16.18.3. E-COMMERCE 16.19. GCC Anti-Obesity Prescription Drugs Market Forecast, By Drug class 16.19.1. Peripherally Acting Anti-obesity Drugs 16.19.2. Centrally Acting Anti-obesity Drugs 16.20. GCC Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 16.20.1. Direct Channel 16.20.2. Distribution Channel 16.21. South Africa Anti-Obesity Prescription Drugs Market Forecast, By Type 16.21.1. PRESCRIPTION DRUGS 16.21.2. OTC Drugs 16.22. South Africa Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 16.22.1. Contrave 16.22.2. Belviq 16.22.3. Xenical 16.22.4. Saxenda 16.22.5. Qsymia 16.23. South Africa Anti-Obesity Prescription Drugs Market Forecast, By Application 16.23.1. HOSPITALS PHARMACIES 16.23.2. RETAIL PHARMACIES 16.23.3. E-COMMERCE 16.24. South Africa Anti-Obesity Prescription Drugs Market Forecast, By Drug class 16.24.1. Peripherally Acting Anti-obesity Drugs 16.24.2. Centrally Acting Anti-obesity Drugs 16.25. South Africa Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 16.25.1. Direct Channel 16.25.2. Distribution Channel 16.26. Rest of Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Type 16.26.1. PRESCRIPTION DRUGS 16.26.2. OTC Drugs 16.27. Rest of Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 16.27.1. Contrave 16.27.2. Belviq 16.27.3. Xenical 16.27.4. Saxenda 16.27.5. Qsymia 16.28. Rest of Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Application 16.28.1. HOSPITALS PHARMACIES 16.28.2. RETAIL PHARMACIES 16.28.3. E-COMMERCE 16.29. Rest of Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Drug class 16.29.1. Peripherally Acting Anti-obesity Drugs 16.29.2. Centrally Acting Anti-obesity Drugs 16.30. Rest of Middle East & Africa Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 16.30.1. Direct Channel 16.30.2. Distribution Channel 16.31. Middle East & Africa Anti-Obesity Prescription Drugs Market Attractiveness Analysis 16.31.1. By Type 16.31.2. By Drug Type 16.31.3. By Application 16.31.4. By Drug class 16.31.5. By Sales channel 16.32. PEST Analysis 16.33. Key Trends 16.34. Key Developments 17. South America Anti-Obesity Prescription Drugs Market Analysis 17.1. Key Findings 17.2. South America Anti-Obesity Prescription Drugs Market Overview 17.3. South America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Type 17.4. South America Anti-Obesity Prescription Drugs Market Forecast, By Type 17.4.1. PRESCRIPTION DRUGS 17.4.2. OTC Drugs 17.5. South America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug Type 17.6. South America Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 17.6.1. Contrave 17.6.2. Belviq 17.6.3. Xenical 17.6.4. Saxenda 17.6.5. Qsymia 17.7. South America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Application 17.8. South America Anti-Obesity Prescription Drugs Market Forecast, By Application 17.8.1. HOSPITALS PHARMACIES 17.8.2. RETAIL PHARMACIES 17.8.3. E-COMMERCE 17.9. South America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Drug class 17.10. South America Anti-Obesity Prescription Drugs Market Forecast, By Drug class 17.10.1. Peripherally Acting Anti-obesity Drugs 17.10.2. Centrally Acting Anti-obesity Drugs 17.11. South America Anti-Obesity Prescription Drugs Market Value Share Analysis, By Sales channel 17.12. South America Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 17.12.1. Direct Channel 17.12.2. Distribution Channel 17.13. South America Anti-Obesity Prescription Drugs Market Value Share Analysis, by Country 17.14. South America Anti-Obesity Prescription Drugs Market Forecast, by Country 17.14.1. Brazil 17.14.2. Mexico 17.14.3. Rest of South America 17.15. South America Anti-Obesity Prescription Drugs Market Analysis, by Country 17.16. Brazil Anti-Obesity Prescription Drugs Market Forecast, By Type 17.16.1. PRESCRIPTION DRUGS 17.16.2. OTC Drugs 17.17. Brazil Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 17.17.1. Contrave 17.17.2. Belviq 17.17.3. Xenical 17.17.4. Saxenda 17.17.5. Qsymia 17.18. Brazil Anti-Obesity Prescription Drugs Market Forecast, By Application 17.18.1. HOSPITALS PHARMACIES 17.18.2. RETAIL PHARMACIES 17.18.3. E-COMMERCE 17.19. Brazil Anti-Obesity Prescription Drugs Market Forecast, By Drug class 17.19.1. Peripherally Acting Anti-obesity Drugs 17.19.2. Centrally Acting Anti-obesity Drugs 17.20. Brazil Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 17.20.1. Direct Channel 17.20.2. Distribution Channel 17.21. Mexico Anti-Obesity Prescription Drugs Market Forecast, By Type 17.21.1. PRESCRIPTION DRUGS 17.21.2. OTC Drugs 17.22. Mexico Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 17.22.1. Contrave 17.22.2. Belviq 17.22.3. Xenical 17.22.4. Saxenda 17.22.5. Qsymia 17.23. Mexico Anti-Obesity Prescription Drugs Market Forecast, By Application 17.23.1. HOSPITALS PHARMACIES 17.23.2. RETAIL PHARMACIES 17.23.3. E-COMMERCE 17.24. Mexico Anti-Obesity Prescription Drugs Market Forecast, By Drug class 17.24.1. Peripherally Acting Anti-obesity Drugs 17.24.2. Centrally Acting Anti-obesity Drugs 17.25. Mexico Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 17.25.1. Direct Channel 17.25.2. Distribution Channel 17.26. Rest of South America Anti-Obesity Prescription Drugs Market Forecast, By Type 17.26.1. PRESCRIPTION DRUGS 17.26.2. OTC Drugs 17.27. Rest of South America Anti-Obesity Prescription Drugs Market Forecast, By Drug Type 17.27.1. Contrave 17.27.2. Belviq 17.27.3. Xenical 17.27.4. Saxenda 17.27.5. Qsymia 17.28. Rest of South America Anti-Obesity Prescription Drugs Market Forecast, By Application 17.28.1. HOSPITALS PHARMACIES 17.28.2. RETAIL PHARMACIES 17.28.3. E-COMMERCE 17.29. Rest of South America Anti-Obesity Prescription Drugs Market Forecast, By Drug class 17.29.1. Peripherally Acting Anti-obesity Drugs 17.29.2. Centrally Acting Anti-obesity Drugs 17.30. Rest of South America Anti-Obesity Prescription Drugs Market Forecast, By Sales channel 17.30.1. Direct Channel 17.30.2. Distribution Channel 17.31. South America Anti-Obesity Prescription Drugs Market Attractiveness Analysis 17.31.1. By Type 17.31.2. By Drug Type 17.31.3. By Application 17.31.4. By Drug class 17.31.5. By Sales channel 17.32. PEST Analysis 17.33. Key Trends 17.34. Key Developments 18. Company Profiles 18.1. Market Share Analysis, by Company 18.2. Competition Matrix 18.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 18.2.2. New Product Launches and Product Enhancements 18.2.3. Market Consolidation 18.2.3.1. M&A by Regions, Investment and Applications 18.2.3.2. M&A Key Players, Forward Integration and Backward Integration 18.3. Company Profiles: Key Players 18.3.1. Arena Pharmaceuticals 18.3.1.1. Company Overview 18.3.1.2. Financial Overview 18.3.1.3. Product Portfolio 18.3.1.4. Business Strategy 18.3.1.5. Recent Developments 18.3.1.6. Manufractring Footprint 18.3.2. F Hoffmann La Roche 18.3.3. Orexigen Therapeutics 18.3.4. Phentermine and Topiramate 18.3.5. VIVUS, Inc 18.3.6. Liraglutide 18.3.7. Bupropion and Naltrexone 18.3.8. Orlistat 18.3.9. Norgine bv 18.3.10. Novo Nordisk 18.3.11. Lorcaserin 18.3.12. GlaxoSmith Kline 18.3.13. Eisai Co, Ltd 18.3.14. Boehringer Ingelheim 18.3.15. Merck & Co 18.3.16. Pfizer 18.3.17. Rhythm Pharmaceuticals 18.3.18. Zafgan 18.3.19. Takeda Pharmaceuticals 18.3.20. Novo Nordisk 18.3.21. Bristol-Myers Squibb Co. 18.3.22. Shionogi USA Inc 19. Primary Key Insights